Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third ...
The long-term complications of pneumonia can be effectively managed through a personalized, multidisciplinary approach that ...
Hepatopulmonary Syndrome: Update on Recent Advances in Pathophysiology, Investigation, and Treatment
In summary, pulmonary vasodilation in experimental HPS is mediated by a number of endogenous vasoactive molecules, including ET-1 and NO (Fig. 2). Liver injury stimulates release of ET-1 ...
A new study demonstrates how AlveoliX’ Lung-on-Chip model offers a more accurate and predictive approach to investigating respiratory diseases and testing potential treatments. AMYRA successfully ...
Sanja Jelic, MD, is a board-certified pulmonologist and sleep specialist who teaches in the Division of Pulmonary, Allergy, and Critical Care Medicine at the Columbia University College of ...
Pulmonary alveolar proteinosis is caused by a buildup in the lungs’ alveoli of a substance called surfactant that’s made up of proteins and lipids. The buildup can block air from moving ...
As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas ... in Phase 3 development for autoimmune Pulmonary Alveolar Proteinosis (aPAP). Molgramostim is delivered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback